HB1115 would create a new Universal Immunization Funding Program within the Hawaii Department of Health and establish a dedicated Universal Immunization Purchase Special Fund to pay for immunizations for eligible residents. The bill is modeled on “universal purchase” or “universal select” programs used in other states, where the state buys vaccines at discounted federal contract prices and makes them available to providers at no cost for administration to people who are not otherwise covered by existing federal or state vaccine programs.
The measure defines the population and entities involved, including child and adult covered lives, assessed entities, health carriers, health maintenance organizations, and health cost sharing programs. It directs the director of health to calculate annual assessments on covered lives, collect payments from insurers and similar entities, maintain a list of covered immunizations, and oversee reporting, audits, and enforcement. The bill also authorizes interim assessments for new vaccines or public health emergencies, requires reporting to the Hawaii immunization registry, and limits provider billing for vaccines supplied through the program.
In terms of state law, HB1115 would add a new part to chapter 321, Hawaii Revised Statutes, and create a new funding mechanism that shifts vaccine procurement costs to assessed health entities rather than direct provider purchase. It also includes appropriations from general revenues and from the new special fund for startup and initial procurement costs, though the dollar amounts are left blank in the text provided. The bill would take effect on July 1, 3000, which appears to function as a placeholder or delayed effective date rather than an immediate implementation date.
The overall sentiment reflected in the bill text is favorable toward the program, emphasizing public health benefits, lower administrative burden for providers, and improved access during shortages or emergencies. Because there are no committee transcripts or recorded votes provided, there is no direct evidence of opposition or support from legislators in the available context. The bill’s findings frame the proposal as a worthwhile public health investment, suggesting a generally pro-immunization and pro-state-administration approach.
The main points of potential contention are the financing and administrative obligations imposed on insurers and related entities, including monthly per-covered-life assessments, reporting requirements, audits, penalties, and interest for nonpayment. Another possible issue is the scope of state authority over vaccine purchasing, inventory management, and provider billing restrictions, as well as the inclusion of self-insured and health cost sharing arrangements in the assessment structure. These provisions could raise concerns about cost shifting, regulatory burden, and implementation complexity, even though no specific objections are recorded in the materials provided.
HB1115 would amend Hawaii law by adding a new statutory program in chapter 321 and creating a universal immunization purchase special fund administered by the Department of Health. It would authorize the department to purchase vaccines, collect assessments from specified insurers and health-related entities, require reporting and audits, impose civil penalties for noncompliance, and regulate which immunizations are covered and how providers may bill for them. The bill would also appropriate state funds for startup and initial vaccine procurement, shifting part of the cost of immunization access from providers and patients to a state-managed pooled funding system.
The bill’s stated purpose and findings reflect strong support for expanding immunization access and reducing provider administrative costs, indicating a generally favorable policy posture toward universal vaccine purchasing. No committee testimony or vote record was provided, so there is no documented legislative opposition or recorded debate in the available materials. Based on the text alone, the measure appears to be framed as a public health and access initiative rather than a controversial partisan proposal.
The most likely areas of contention are the mandatory assessments on insurers, HMOs, mutual benefit societies, fraternal benefit societies, self-insured plans, and health cost sharing programs, since these entities would finance the program through per-covered-life charges. Stakeholders could also object to the reporting, audit, and enforcement provisions, including interest on late payments and civil fines, as well as the restriction that providers may not bill for vaccines supplied at no cost by the state. Another possible point of debate is the breadth of the Department of Health’s authority to determine covered immunizations, set interim assessments, and manage vaccine purchasing and inventory.